Willemse PH - Search Results

1

Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer.

Gietema JA, Sleijfer DT, Willemse PH, Schraffordt Koops H, van Ittersum E, Verschuren WM, Kromhout D, Sluiter WJ, Mulder NH, de Vries EG. Gietema JA, et al. Among authors: willemse ph. Ann Intern Med. 1992 May 1;116(9):709-15. doi: 10.7326/0003-4819-116-9-709. Ann Intern Med. 1992. PMID: 1558341

2

Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage.

de Vos FY, Nuver J, Willemse PH, van der Zee AG, Messerschmidt J, Burgerhof JG, de Vries EG, Gietema JA. de Vos FY, et al. Among authors: willemse ph. Eur J Cancer. 2004 Mar;40(5):696-700. doi: 10.1016/j.ejca.2003.11.026. Eur J Cancer. 2004. PMID: 15010070

3

Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.

Biesma B, Willemse PH, Mulder NH, Sleijfer DT, Gietema JA, Mull R, Limburg PC, Bouma J, Vellenga E, de Vries EG. Biesma B, et al. Among authors: willemse ph. Blood. 1992 Sep 1;80(5):1141-8. Blood. 1992. PMID: 1515636 Free article.

4

A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.

Willemse PH, Sleijfer DT, de Vries EG, Boonstra H, Bouma J, Mulder NH. Willemse PH, et al. Eur J Cancer. 1992;28(2-3):479-81. doi: 10.1016/s0959-8049(05)80081-4. Eur J Cancer. 1992. PMID: 1591067 Clinical Trial.

5

Children born after their fathers had been treated with chemotherapy for testicular cancer.

van der Kolk BM, Mulder NH, Mantingh A, van den Berg E, Schraffordt Koops H, de Vries EG, Willemse PH, Sleijfer DT. van der Kolk BM, et al. Among authors: willemse ph. Eur J Obstet Gynecol Reprod Biol. 1990 Jan-Feb;34(1-2):167-70. doi: 10.1016/0028-2243(90)90020-2. Eur J Obstet Gynecol Reprod Biol. 1990. PMID: 1689259

6

Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma.

Gietema JA, Willemse PH, Mulder NH, Oldhoff J, de Vries EG, Sleijfer DT. Gietema JA, et al. Among authors: willemse ph. Eur J Cancer. 1991;27(11):1376-9. doi: 10.1016/0277-5379(91)90013-4. Eur J Cancer. 1991. PMID: 1720634

7

CA-125 in ovarian cancer: relation between half-life, doubling time and survival.

Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de Vries EG. Willemse PH, et al. Eur J Cancer. 1991;27(8):993-5. doi: 10.1016/0277-5379(91)90266-g. Eur J Cancer. 1991. PMID: 1832911

8

Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis.

Willemse PH, van Lith J, Mulder NH, Aalders JG, Bouma J, de Vries EG, Sleijfer DT. Willemse PH, et al. Eur J Cancer. 1990 Mar;26(3):345-52. doi: 10.1016/0277-5379(90)90232-i. Eur J Cancer. 1990. PMID: 2141492

9

Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.

Mulder NH, Sleijfer DT, de Vries EG, Schraffordt Koops H, Willemse PH. Mulder NH, et al. Among authors: willemse ph. J Cancer Res Clin Oncol. 1990;116(3):301-2. doi: 10.1007/BF01612907. J Cancer Res Clin Oncol. 1990. PMID: 2196265

10

Long-term survival after vinblastine, bleomycin, and cisplatin treatment in patients with germ cell tumors of the ovary: an update.

Willemse PH, Aalders JG, Bouma J, Mulder NH, Verschueren RC, de Vries EG, Sleijfer DT. Willemse PH, et al. Gynecol Oncol. 1987 Nov;28(3):268-77. doi: 10.1016/0090-8258(87)90172-7. Gynecol Oncol. 1987. PMID: 2445635

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters